EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One ® Robotic HIFU in Radiorecurrent Prostate Cancer. AUSTIN, ...

Non-inferior salvage treatment–free survival at 30 months favored HIFU (90%) versus salvage radical prostatectomy (86%), ...

Sonire Therapeutics, a U.S.-based clinical-stage medical device company, today announced the initiation of its first U.S. clinical trial, SUNRISE-II, evaluating its proprietary High-Intensity Focused ...

Sonire Therapeutics announced today that it initiated its first U.S. clinical trial, SUNRISE-II, evaluating its pancreatic ...

Sonablate, a medical technology company focused on non-invasive prostate cancer treatment using high-intensity focused ultrasound (HIFU) , today announced the appointment of Brad Saar, former ...

SAN ANTONIO -- A comparison of high-intensity focused ultrasound (HIFU) and radical prostatectomy (RP) found that HIFU was non-inferior to surgery as primary treatment for localized prostate cancer, ...

One in eight men will develop prostate cancer in their lifetime. Surgery to treat the disease can lead to unwelcome side effects. A minimally invasive alternative that avoids surgery is now available ...

GOOD MORNING TO YOU. I’M SHAQUILLE LORD. TODAY I’M JOINED BY DOCTOR JUSTIN PHILLIPS. HE’S HERE TO TALK ABOUT THE HIGHVIEW. OPEN HOUSE IS HAPPENING AT BROWNSBORO HOSPITAL THURSDAY, OCTOBER 2ND. DOCTOR ...

Through successful integration and execution, Classys has established a business model that combines high growth (30%+ CAGR) ...

Sonire Therapeutics raised $18 million in a Series A financing round to support its high-intensity focused ultrasound (HIFU) therapy system.

CLEVELAND, Ohio (Ivanhoe Newswire) - After skin cancer, prostate cancer is the most common cancer in men in the US. For the men who have beat prostate cancer once, 20 to 30 percent will show signs of ...